Title: Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017 Document date: 2017_11_7
ID: roslkxeq_649
Snippet: Disclosures: No disclosures to report. Inflammatory mammary cancer (IMC) is a specific type of locally advanced mammary cancer in dogs. It is an uncommon tumor, but the most aggressive type of mammary cancer in female dogs with an extremely poor survival rate. No effective treatment has been reported for dogs with IMC and surgery is not indicated as first option. Based on the different molecular features of these highly angiogenic cancer, new the.....
Document: Disclosures: No disclosures to report. Inflammatory mammary cancer (IMC) is a specific type of locally advanced mammary cancer in dogs. It is an uncommon tumor, but the most aggressive type of mammary cancer in female dogs with an extremely poor survival rate. No effective treatment has been reported for dogs with IMC and surgery is not indicated as first option. Based on the different molecular features of these highly angiogenic cancer, new therapies focused on specific targets has been proposed. The aim of this study was to evaluate the survival time in dogs diagnosed with IMC treated with a multimodal therapy based on an anti-COX2 drug (firocoxib), a tyrosine kinase inhibitor (toceranib) and an androgen receptor inhibitor (flutamide).
Search related documents:
Co phrase search for related documents- specific target and survival rate: 1, 2, 3
- specific target and tyrosine kinase: 1, 2, 3, 4, 5, 6
- specific target and tyrosine kinase inhibitor: 1, 2
- specific type and study aim: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- specific type and survival rate: 1, 2
- specific type and tyrosine kinase: 1
- study aim and survival rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- study aim and survival time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45
- study aim and toceranib tyrosine kinase inhibitor: 1
- study aim and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- study aim and tyrosine kinase inhibitor: 1, 2, 3, 4, 5, 6
- study aim and uncommon tumor: 1
- survival rate and tyrosine kinase: 1, 2, 3, 4, 5, 6, 7, 8
- survival rate and tyrosine kinase inhibitor: 1, 2
- survival time and tyrosine kinase: 1, 2, 3, 4, 5, 6
- survival time and tyrosine kinase inhibitor: 1, 2
- survival time and uncommon tumor: 1, 2
Co phrase search for related documents, hyperlinks ordered by date